Dr Kevan Herold Explains Teplizumab's Potential in Newly Diagnosed T1D

Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine, discussed recently published results from the PROTECT trial of teplizumab in patients newly diagnosed with type 1 diabetes (T1D).

Related Keywords

Kevan Herold ,Yale School Of Medicine ,Yale School ,Teplizumab ,Type 1 Diabetes ,